AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Axsome Therapeutics Inc. (AXSM)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

128.46

-2.69 (-2.05%)

At close: Feb 18, 2025, 3:59 PM

128.09

-0.29%

After-hours: Feb 18, 2025, 04:00 PM EST

undefined% (undefined)

Bid	126.18
Market Cap	6.23B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-6.58
PE Ratio (ttm)	-19.52
Forward PE	n/a
Analyst	Buy

Ask	130
Volume	1,268,528
Avg. Volume (20D)	866,835
Open	124.66
Previous Close	131.15
Day's Range	124.03 - 130.15
52-Week Range	64.11 - 134.19
Beta	undefined

About AXSM

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial ...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Nov 19, 2015

Employees 607

Stock Exchange NASDAQ

Ticker Symbol AXSM

Website https://www.axsome.com

Full Company Profile

Analyst Forecast

According to 15 analyst ratings, the average rating for AXSM stock is "Buy." The 12-month stock price forecast is $143, which is an increase of 11.32% from the latest price.

Buy 93.33%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Axsome Therapeutics Inc. is scheduled to release its earnings on May 5, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 week ago

+4.03%

Axsome Therapeutics shares are trading higher afte... Unlock content with Pro Subscription

1 week ago

+20.16%

Axsome Therapeutics shares are trading higher after the company reached a settlement agreement with Teva Pharmaceuticals resolving all patent litigation related to its Auvelity product.

News

19 hours ago · zacks.com

Axsome Q4 Loss Wider Than Expected, Auvelity Drives Sales Growth

AXSM's fourth-quarter 2024 earnings miss estimates while revenues beat the same. Net product sales rise year over year.

20 hours ago · seekingalpha.com

Axsome Therapeutics, Inc. (AXSM) Q4 2024 Earnings Call Transcript

Axsome Therapeutics, Inc. (NASDAQ:AXSM ) Q4 2024 Earnings Conference Call February 18, 2025 8:00 AM ET Company Participants Darren Opland - Director, Corporate Communications Herriot Tabuteau - Chief ...

22 hours ago · zacks.com

Axsome Therapeutics (AXSM) Reports Q4 Loss, Tops Revenue Estimates

Axsome Therapeutics (AXSM) came out with a quarterly loss of $0.96 per share versus the Zacks Consensus Estimate of a loss of $1. This compares to loss of $0.73 per share a year ago.

23 hours ago · fool.com

Axsome Therapeutics Revenue Surges 66%

Biopharmaceutical firm Axsome Therapeutics (AXSM -0.40%) reported mixed fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 18. The company achieved substantial revenue growth, with sales hitt...

1 day ago · zacks.com

Will These 5 Biotech Stocks Surpass Q4 Earnings Forecast?

Let's look at five biotech and drug companies, AXSM, HALO, FOLD, BMRN and INSM, slated to release their fourth-quarter 2024 results this week.

2 days ago · fool.com

This Stock Is Already Up by 55% in 2025: Is It Too Late to Buy?

It's only mid-February, but as of this writing biotech company Axsome Therapeutics (AXSM -0.40%) is up by 55% year to date. Substantial stock-market gains over short periods aren't that rare in the in...

1 week ago · seekingalpha.com

Axsome Settling Teva Patent Litigation Is Another Positive Catalyst -- Upgrade

Axsome Therapeutics, Inc.'s stock has surged over 30% since my last “Hold” rating, driven by key catalysts like the litigation settlement with Teva Pharmaceuticals, announced today. Axsome's Auvelity ...

1 week ago · fool.com

Why Axsome Therapeutics Stock Is Soaring Today

Shares of Axsome Therapeutics (AXSM 4.36%) are up on Tuesday. The company's stock gained 4.1% as of 10:20 a.m.

1 week ago · zacks.com

Earnings Preview: Axsome Therapeutics (AXSM) Q4 Earnings Expected to Decline

Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 week ago · zacks.com

Axsome Stock Surges 20% on Auvelity Patent Settlement With Teva

AXSM stock rises 20% as it settles Auvelity patent litigation with Teva, protecting the drug's exclusivity in the United States at least until Sept. 30, 2038.

Load More News